| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.3 | 4e-16 |
| mRNA | BRD-K02251932 | CTRPv2 | pan-cancer | AAC | 0.18 | 3e-06 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.11 | 5e-05 |
| mRNA | QW-BI-011 | CTRPv2 | pan-cancer | AAC | 0.26 | 5e-05 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Doxorubicin | gCSI | pan-cancer | AAC | -0.18 | 0.0006 |
| mRNA | decitabine:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.1 | 0.0007 |
| mRNA | QL-VIII-58 | GDSC1000 | pan-cancer | AAC | -0.15 | 0.0008 |